Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of PMS-101 Administration in Patients With Burn(s)

NCT06440239 is registered in ClinicalTrials.gov with Primoris Therapeutics as lead sponsor.

NCT NCT06440239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06440239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of PMS-101 Administration in Patients With Burn(s)
Lead sponsor
Primoris Therapeutics
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 1, 2025
Completion date
February 28, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burn degree second, burns